

CARE VALUE POLICY

POLICY: Hereditary Angioedema – Icatibant (Firazyr) Care Value Policy

- Firazyr® (icatibant subcutaneous injection – Takeda, generic)

REVIEW DATE: 08/25/2021

OVERVIEW

Icatibant (Firazyr, generic) is a synthetic decapeptide that is indicated for the **treatment of acute hereditary angioedema (HAE) attacks** in adults ≥ 18 years of age.¹

POLICY STATEMENT

This Care Value program has been developed to encourage the use of the Preferred Product. For Non-Preferred medications, the patient is required to meet the standard *Prior Authorization Policy* criteria. The program also directs the patient to try the Preferred Product prior to approval of the Non-Preferred Product. Requests for Non-Preferred Products will be reviewed using the exception criteria (below). All approvals are provided for the duration noted below. Of note, only Non-Preferred Products are required to undergo Prior Authorization.

Documentation: Documentation will be required where noted in the criteria as **[documentation required]**. Documentation may include, but is not limited to, chart notes, prescription claims records, and prescription receipts.

Automation: None.

Preferred Product: generic icatibant
Non-Preferred Product: Firazyr

RECOMMENDED EXCEPTION CRITERIA

Non-Preferred Product	Exception
Firazyr	<ol style="list-style-type: none">1. Approve for 1 year if the patient meets ALL of the following (A, B, and C):<ol style="list-style-type: none">A) Patient meets the standard <i>Hereditary Angioedema – Icatibant (Firazyr) Prior Authorization Policy</i> criteria; ANDB) Patient has tried generic icatibant [documentation required]; ANDC) The Brand product is being requested due to a formulation difference in the inactive ingredient(s) [e.g., differences in stabilizing agent, buffering agent, and/or surfactant] between the Brand and the bioequivalent generic product which, per the prescriber, would result in a significant allergy or serious adverse reaction [documentation required].

REFERENCES

1. Firazyr[®] [prescribing information]. Lexington, MA: Takeda; August 2020.